奥拉帕利联合TP化疗治疗晚期卵巢癌患者的疗效及毒副反应分析  

Efficacy and side effects of olaparide combined with TP Chemotherapy in patients with advanced ovarian cancer

作　　者：丁倩 陈燕[1] 戴萍[1] Ding Qian;Chen Yan;Dai Ping(Department of Pharmacy,Jiangdu People's Hospital of Hangzhou,Jiangdu 225200,China)

机构地区：[1]扬州市江都人民医院药剂科,江苏江都225200

出　　处：《实用妇科内分泌电子杂志》2022年第18期54-56,共3页Electronic Journal of Practical Gynecological Endocrinology

基　　金：2020江苏省药学会奥赛康临床药学基金科研(编号A202043)。

摘　　要：目的探究晚期卵巢癌患者采取奥拉帕利联合TP化疗治疗的效果,并分析其毒副反应。方法选取145例晚期卵巢癌患者,按照随机数字表法分为对照组(71例)与研究组(74例)。对照组患者接受TP化疗治疗,研究组患者接受奥拉帕利联合TP化疗治疗。比较两组患者临床疗效率、疾病控制率,同时观察记录患者化疗治疗期间出现的毒副反应,随访6个月,记录患者疾病复发率。结果研究组患者总体临床疗效率、疾病控制率各为70.27%、89.19%,均高于对照组的53.52%、69.01%,差异有统计学意义(P<0.05)。研究组患者贫血发生率高于对照组,差异有统计学意义(P<0.05),两组恶心呕吐、脱发、骨髓抑制、白细胞减少、肝肾损伤发生率比较,差异无统计学意义(P>0.05)。随访6个月,研究组疾病复发率低于对照组,差异有统计学意义(P<0.05)。结论晚期卵巢癌患者运用奥拉帕利联合TP化疗治疗的疗效可靠,且药物毒副反应较少,疾病复发率较低,值得临床推广与应用。Objective To explore the effect of combining olapali with TP chemotherapy in patients with advanced ovarian cancer, and to analyze the toxic side effects. Methods 145 patients with advanced ovarian cancer were selected and divided into control group(71 cases) and study group(74 cases) according to random number table method. The control group received TP chemotherapy, and the study group received olaparil combined with TP chemotherapy. The clinical efficacy rate and disease control rate of the two groups were compared. The toxic and side effects of the patients during chemotherapy were observed and recorded.The patients were followed up for 6 months and the disease recurrence rate was recorded. Results The overall clinical efficacy rate and disease control rate of the study group were 70.27% and 89.19%, respectively, higher than those of the control group(53.52%and 69.01%), and the difference was statistically significant(P<0.05). The incidence of anemia in the study group was higher than that in the control group, the difference was statistically significant(P<0.05), but there was no statistically significant difference in the incidence of nausea and vomiting, alopecia, myelosuppression, leukopenia, liver and kidney injury between the two groups(P>0.05). After 6 months of follow-up, the recurrence rate of the study group was lower than that of the control group, and the difference was statistically significant(P<0.05). Conclusion Olaparil combined with TP chemotherapy in the treatment of advanced ovarian cancer patients has a reliable curative effect, less drug toxicity and side effects, and a low recurrence rate, which is worthy of clinical promotion and application.

关 键 词：晚期卵巢癌 奥拉帕利 TP化疗 临床疗效 毒副反应 复发率 

分 类 号：R737.31[医药卫生—肿瘤]